|
|
|
0 members (),
543
guests, and
27
robots. |
|
Key:
Admin,
Global Mod,
Mod
|
|
S |
M |
T |
W |
T |
F |
S |
|
|
|
|
1
|
2
|
3
|
4
|
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
|
27
|
28
|
29
|
30
|
31
|
|
|
There are no members with birthdays on this day. |
#220726
Tue 06 May 2014 01:48:PM
|
Joined: Feb 2001
Posts: 381,903
Launch Director
|
OP
Launch Director
Joined: Feb 2001
Posts: 381,903 |
A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier 'proof of concept' clinical trial using exenatide showed that improvements persisted 12 months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers.  Source: Exenatide has potential as disease modifying agent in Parkinson's disease
David Cottle
UBB Owner & Administrator
|
|
CMS The Best Conveyancing solicitors conveyancing quotes throughout the UK
For any webhosting enquiries please email webmaster@aus-city.com
|
|
Forums60
Topics685,194
Posts719,805
Members2,957
| |
Most Online3,142
Jan 16th, 2023
|
|
|
|
|
Copyright 1996 - 2023 by David Cottle. Designed by David Bate Jr. All Rights Reserved.
By using this forum, the user agrees not to transfer any data or technical information received under the agreement, to any other entity without the express approval of the AUS-CITY Forum Admins and/or authors of individual posts (Forum Admins and DoD/USSPACECOM for the analysis of satellite tracking data).
Two-line elements (TLE) and all other satellite data presented and distributed via this forum and e-mail lists of AUS-CITY are distributed with permission from DoD/USSTRATCOM.
Reprise Hosting
|
|
